Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: PDT, CXP, IMA

CLEW Registered for CE Expanding its Commercial Reach in the European market


TEL AVIV, Israel, March 10, 2021 /PRNewswire/ -- CLEW announced that it has registered its AI-powered ICU clinical management and support solution for CE, marking the company's further expansion into the European healthcare market. Registration of the full range of CLEW's advanced, AI-based predictive analytics solution will enable centralized critical care management leveraging all available patient data, providing clinical optimization for effective treatment and acuity-based resource allocation.

To improve the efficiency of the European healthcare system, the innovative CLEWICU solution identifies patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability, prioritizes workflow and treatment, and optimizes the allocation of critical care resources.

It incorporates three models of predictive screening:

CLEWICU solution offers hospitals and caregivers a comprehensive system integrated into the ICU workflow for improved outcomes and clinical resource allocation. It offers a full system view with advanced features in three detailed display screens and integrated audio-visual capabilities to conduct video calls or observation.

Demonstrated value of CLEWICU during the Covid-19 pandemic

The CLEW platform offers significant benefits in both clinical and operational outcomes, based on the following points:

  1. Earlier knowledge of upcoming deterioration leads to early intervention (improved quality and safety of care, less clinical complications, reduction of average LOS)
  2. Risk classification of patients allows for acuity-based staffing and resource assignment
  3. Significantly fewer false alarms may increase staff efficiency, due to less time spent on reacting to alarms, as well as reduced alarm fatigue and burnout
  4. The ability to work-from-anywhere allows shifting of resources from bedside to telehealth, as well as an option to outsource intensivist coverage.

"The coronavirus pandemic has highlighted the need for better management of critical care resources. CLEW's solution will provide the European healthcare system with the tools to effectively manage ICU operations and provide better clinical outcomes, support the decision-making process for treatment, optimize workflow and resource allocation," Gal Salomon, CLEW CEO.

"With our partner CLEW, we share the same goal of improving patient care and safety and are convinced of the need to act in the prevention of clinical risks to influence the quality of care, the performance and the attractiveness of the establishments. Technology now makes it possible to analyse data, identify and anticipate risks much earlier than was previously possible. CLEWICU is an innovative solution that meets the specific needs of the healthcare actors we have been supporting as Risk Manager for more than 90 years in France, but also in Spain, Italy and Germany," Pierre-Yves Antier, Relyens group Strategy, Innovation and Transformation Director and CLEW board member.

To learn more about how machine learning and AI stand to deliver meaningful impact and improve patient value, click here and watch the video.

About CLEW:

Founded in 2015 in Israel, CLEW provides real-time AI analytics platforms designed to help hospitals and care makers perform better informed clinical decisions by predicting life-threatening complications across various medical care settings. CLEW Medical's goal is to provide reliable and proven solutions that can improve clinical outcomes and patient safety, streamline patient care, and efficiently handle regulations and penalties, ultimately lowering the cost of care. Originally developed and proven in the ICU, CLEW will develop machine learning models that have the potential to optimize clinical resources and guide health care providers in predicting patient deterioration, across all care settings.

Connect with us at www.clewmed.com,

on LinkedIn at www.linkedin.com/company/clewmed/,

on Facebook at www.facebook.com/CLEWMedical/, and on Twitter @CLEWMedical.

 

SOURCE CLEW


These press releases may also interest you

at 16:20
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The...

at 16:19
The Autorité des marchés financiers ("AMF") cautions Québec consumers about the website dr-hypotheque.ca.  According to information...

at 16:15
Block, Inc. will release financial results for the second quarter of 2024 on Thursday, August 1, 2024, after market close. Block will also host a conference call and earnings webcast at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time on the same day...

at 16:15
Snap Inc. will hold its quarterly conference call to discuss second quarter 2024 financial results on Thursday, August 1, 2024 at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). A live webcast and replay of the conference call will be accessible...

at 16:10
bluebird bio, Inc. today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James...

at 16:10
AppLovin Corporation, ("AppLovin" or the "Company") the leading marketing platform, today announced it will report financial results for the second quarter on Wednesday, August 7, 2024 after the U.S. stock market closes. An accompanying webinar...



News published on and distributed by: